BioMarker Strategies SnapPath® System
BioMarker Strategies is a tissue-based cancer diagnostics company that is developing the SnapPath® live tumor cell testing system* to improve the treatment of cancer.
Supported with funding from the National Cancer Institute, the SnapPath® system enables the generation of PathMap® Functional Signaling Profiles which help guide targeted drug development and treatment selection, including drug combinations.
SnapPath® units are being utilized in human clinical and preclinical studies for advanced melanoma and other solid tumors.
Service Provided by Sparton:
Biomarker Strategies partnered with the Sparton design and manufacturing teams to develop a system that would standardize and automate biopsy sample preparation and live cell molecular analysis. The detailed services provided by Sparton include:
Full System Design
- Electronics design
- Software design
- Mechanical engineering
- Fluidics system design
- Thermal management design
- Systems engineering
- Disposable development (partnership)
- Prototype builds
- Proven expertise in complex fluidics
- Experience in interfacing the disposable with the instrumentation
- Deep understanding of the FDA regulatory environment
- Specific knowledge in working with in vitro diagnostics devices
The SnapPath® System has been recognized by various industry experts for its novel technology. In one report, SnapPath® is ranked as 1 of 6 promising technologies that will change cancer testing. Sparton is proud to have played a key role in the development of this emerging technology.
*For Research Use Only (RUO) device. Not for use in diagnostic procedures.